Scarica l'app Stockscreener
11.75
1.51%
-0.18
Dopo l'orario di chiusura:
11.75
Precedente Chiudi:
$11.93
Aprire:
$11.9
Volume 24 ore:
204.55K
Relative Volume:
0.25
Capitalizzazione di mercato:
$640.80M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+7.50%
1M Prestazione:
+31.43%
6M Prestazione:
+1.25%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$11.69
$12.01
Intervallo di 1 settimana:
$10.94
$12.03
Portata 52W:
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Nome
Bicara Therapeutics Inc
Settore
Industria
Telefono
617-785-8308
Indirizzo
245 MAIN STREET, CAMBRIDGE
Confronta BCAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
11.75 | 642.98M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-23 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Iniziato | Wells Fargo | Underweight |
| 2025-02-06 | Iniziato | Wedbush | Outperform |
| 2024-12-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
| 2024-10-08 | Iniziato | Stifel | Buy |
| 2024-10-08 | Iniziato | TD Cowen | Buy |
Mostra tutto
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
What analysts say about Bicara Therapeutics Inc. stock outlookHigh-margin investment plays - jammulinksnews.com
Is Bicara Therapeutics Inc. stock a good hedge against inflationExtraordinary profit generation - jammulinksnews.com
Will Bicara Therapeutics Inc. stock benefit from interest rate changesDynamic investment growth - jammulinksnews.com
Is Bicara Therapeutics Inc. a good long term investmentConsistently exceptional gains - Autocar Professional
Bicara Therapeutics Inc. Stock Analysis and ForecastFree Investment Community - jammulinksnews.com
What drives Bicara Therapeutics Inc. stock priceHigh-velocity gains - jammulinksnews.com
What analysts say about Bicara Therapeutics Inc. stockHigh-profit trading signals - jammulinksnews.com
How Bicara Therapeutics Inc. stock performs during market volatilityVolume Spike Monitors - Newser
Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Price Target at $31.86 - Defense World
Why Bicara Therapeutics Inc. stock attracts strong analyst attentionFree Step-by-Step Investment Guide - Newser
What makes Bicara Therapeutics Inc. stock price move sharplyInvestor Friendly Risk Reward - Newser
Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III - Yahoo Finance
GAMMA Investing LLC Purchases 7,694 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Elects New Directors at Annual Meeting - TipRanks
Petri Dish: Scorpion spinout debuts with $177M, Bicara doubles footprint - The Business Journals
# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial - Investing.com
Relay Therapeutics Strengthens Board with Precision Medicine Expert as Phase 3 Cancer Trial Approaches - Stock Titan
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha
Bicara Therapeutics Inc. (NASDAQ:BCAX) Holdings Raised by Bank of America Corp DE - Defense World
Cantor Fitzgerald Estimates BCAX FY2026 Earnings - Defense World
Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update - MSN
Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
Bicara Therapeutics Inc Azioni (BCAX) Dati Finanziari
Non sono disponibili dati finanziari per Bicara Therapeutics Inc (BCAX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Bicara Therapeutics Inc Azioni (BCAX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Meisner Lara | Chief Legal Officer |
Jun 16 '25 |
Sale |
10.43 |
15,829 |
165,096 |
0 |
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):